Navigation Links
Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
Date:1/9/2012

GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development.

Dr. Onakunle will report directly to President and CEO, Dr. Igor Fisch and will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

"Selexis is experiencing a tremendous growth cycle by offering more innovation and long-term value to our customers. Yemi's wealth of business development and sales experience in biologics and cell line development will be instrumental in expanding the SUREtechnology Platform™ into important markets," said Dr. Igor Fisch, CEO of Selexis. "Yemi's understanding of our technology and expanding global customer base makes him an excellent choice for this newly created position."

Dr. Onakunle has over 15 years' experience in drug manufacturing and cell line development. Prior to working at Selexis, Dr. Onakunle was Director of Commercial Development at Diosynth RTP Inc. and Associate Director of Business Development at Lonza Custom Manufacturing – organizations providing process development and cGMP manufacturing services in mammalian production platforms. More recently, Dr. Onakunle was Head of Sales and Marketing at Bachem Americas Inc. - a contract manufacturing organization focusing on peptides and complex organic molecules. In these positions, he has a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Dr. Onakunle is a member of the Board of Directors of VLP Biotech Inc, a vaccine development company based in San Diego, CA and has been a Business Advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Dr. Onakunle holds a Ph.D. from the University of Kent at Canterbury and an M.B.A. from Imperial College Management School.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information, visit http://www.selexis.com

Media Contact:

Robert Meister
robert.meister(at)selexis(dot)com
(602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. Selexis SA to Present at Biotech Showcase 2012
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Omeros Appoints David A. Mann to its Board of Directors
11. RainDance Technologies Appoints Olex Vice President, System Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):